Neuroleptic malignant syndrome in Huntington disease.
Huntington disease
dopamine
neuroleptic malignant syndrome
neuroleptics
tetrabenazine
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
23 Oct 2024
23 Oct 2024
Historique:
revised:
11
07
2024
received:
08
04
2024
accepted:
30
07
2024
medline:
24
10
2024
pubmed:
24
10
2024
entrez:
24
10
2024
Statut:
aheadofprint
Résumé
Despite the wide use of dopamine receptor blocking agents (DRBAs) in Huntington disease (HD), neuroleptic malignant syndrome (NMS) is rarely described in this population. The aim of this study was to assess NMS prevalence in a large cohort of HD patients and explore the main associated risk factors. In 2023, an HD patient was admitted to our neurology department due to NMS. Starting from the case description, we performed a narrative review of the literature of NMS cases in HD, reviewed data from the fifth dataset of the Enroll-HD (a longitudinal, observational, global study of families with HD) study (PDS5) selecting HD patients treated with DRBAs and/or tetrabenazine (TBZ) who presented at least one of the core symptoms of NMS (rigidity and hyperthermia), and collected data to investigate prevalence of NMS and identify risk factors. In the Enroll-HD PDS5 dataset, we identified 5108 of 11,569 HD patients who were undergoing DRBA and/or TBZ treatment. Only one patient, a Caucasian man of 46 years, undergoing clozapine and valproate treatment, had a registered diagnosis of NMS. NMS in HD patients is seldom described. This could be due to an underestimation of this condition. There are no available objective NMS diagnostic criteria at present, and the existence of atypical forms of NMS further complicates diagnosis. Advanced disease stage, rigid-akinetic phenotype, abrupt therapy changes, polytherapy, and dehydration are key risk factors, most of which are preventable through awareness and caution in managing medications in the HD population.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Despite the wide use of dopamine receptor blocking agents (DRBAs) in Huntington disease (HD), neuroleptic malignant syndrome (NMS) is rarely described in this population. The aim of this study was to assess NMS prevalence in a large cohort of HD patients and explore the main associated risk factors.
METHODS
METHODS
In 2023, an HD patient was admitted to our neurology department due to NMS. Starting from the case description, we performed a narrative review of the literature of NMS cases in HD, reviewed data from the fifth dataset of the Enroll-HD (a longitudinal, observational, global study of families with HD) study (PDS5) selecting HD patients treated with DRBAs and/or tetrabenazine (TBZ) who presented at least one of the core symptoms of NMS (rigidity and hyperthermia), and collected data to investigate prevalence of NMS and identify risk factors.
RESULTS
RESULTS
In the Enroll-HD PDS5 dataset, we identified 5108 of 11,569 HD patients who were undergoing DRBA and/or TBZ treatment. Only one patient, a Caucasian man of 46 years, undergoing clozapine and valproate treatment, had a registered diagnosis of NMS.
CONCLUSIONS
CONCLUSIONS
NMS in HD patients is seldom described. This could be due to an underestimation of this condition. There are no available objective NMS diagnostic criteria at present, and the existence of atypical forms of NMS further complicates diagnosis. Advanced disease stage, rigid-akinetic phenotype, abrupt therapy changes, polytherapy, and dehydration are key risk factors, most of which are preventable through awareness and caution in managing medications in the HD population.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e16442Informations de copyright
© 2024 The Author(s). European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Bates GP, Dorsey R, Gusella JF, et al. Huntington disease. Nat Rev Dis Primer. 2015;1:1‐21. doi:10.1038/nrdp.2015.5
Vogt C, Vogt O. Precipitating and modifying agents in chorea. J Nerv Ment Dis. 1952;116:601‐607. doi:10.1097/00005053-195212000-00015
Kremer HPH, Roos RAC, Dingjan G, Bots GTAM, Maran E. Atrophy of the hypothalamic lateral Tuberal nucleus in Huntington's disease. J Neuropathol Exp Neurol. 1990;49:371‐382. doi:10.1097/00005072-199007000-00002
Kremer HPH, Roos RAC, Dingjan GM, Bots GTAM, Bruyn GW, Hofman MA. The hypothalamic lateral tuberal nucleus and the characteristics of neuronal loss in Huntington's disease. Neurosci Lett. 1991;132:101‐104. doi:10.1016/0304-3940(91)90443-W
Douaud G, Gaura V, Ribeiro M‐J, et al. Distribution of grey matter atrophy in Huntington's disease patients: a combined ROI‐based and voxel‐based morphometric study. Neuroimage. 2006;32:1562‐1575. doi:10.1016/j.neuroimage.2006.05.057
Soneson C, Fontes M, Zhou Y, et al. Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis. Neurobiol Dis. 2010;40:531‐543. doi:10.1016/j.nbd.2010.07.013
Politis M, Pavese N, Tai YF, Tabrizi SJ, Barker RA, Piccini P. Hypothalamic involvement in Huntington's disease: an in vivo PET study. Brain J Neurol. 2008;131:2860‐2869. doi:10.1093/brain/awn244
Goodman AOG, Murgatroyd PR, Medina‐Gomez G, et al. The metabolic profile of early Huntington's disease–a combined human and transgenic mouse study. Exp Neurol. 2008;210:691‐698. doi:10.1016/j.expneurol.2007.12.026
Weydt P, Dupuis L, Petersen Å. Thermoregulatory disorders in Huntington disease. Handb Clin Neurol. 2018;157:761‐775. doi:10.1016/B978-0-444-64074-1.00047-1
Strawn JR, Keck PE, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007;164:870‐876. doi:10.1176/ajp.2007.164.6.870
Tse L, Barr AM, Scarapicchia V, Vila‐Rodriguez F. Neuroleptic malignant syndrome: a review from a clinically oriented perspective. Curr Neuropharmacol. 2015;13:395‐406. doi:10.2174/1570159x13999150424113345
Andriessen RL, Oosterloo M, Hollands A, Linden DEJ, de Greef BTA, Leentjens AFG. Psychotropic medication use in Huntington's disease: a retrospective cohort study. Parkinsonism Relat Disord. 2022;105:69‐74. doi:10.1016/j.parkreldis.2022.11.004
Désaméricq G, Youssov K, Charles P, et al. Guidelines for clinical pharmacological practices in Huntington's disease. Rev Neurol (Paris). 2016;172:423‐432. doi:10.1016/j.neurol.2016.07.012
Mateo D, Muñoz‐Blanco JL, Giménez‐Roldán S. Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington's disease. Clin Neuropharmacol. 1992;15:63‐68. doi:10.1097/00002826-199202000-00009
Musco S, Ruekert L, Myers J, Anderson D, Welling M, Cunningham EA. Characteristics of patients experiencing extrapyramidal symptoms or other movement disorders related to dopamine receptor blocking agent therapy. J Clin Psychopharmacol. 2019;39:336‐343. doi:10.1097/JCP.0000000000001061
Dressler D, Benecke R. Diagnosis and management of acute movement disorders. J Neurol. 2005;252:1299‐1306. doi:10.1007/s00415-005-0006-x
Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH. Neuroleptic malignant syndrome caused by dopamine‐depleting drugs in a patient with Huntington disease. Neurology. 1981;31:1022‐1025. doi:10.1212/wnl.31.8.1022
Ossemann M, Sindic CJ, Laterre C. Tetrabenazine as a cause of neuroleptic malignant syndrome. Mov Disord Off J Mov Disord Soc. 1996;11:95. doi:10.1002/mds.870110118
Gaasbeek D, Naarding P, Stor T, Kremer HPH. Drug‐induced hyperthermia in Huntington's disease. J Neurol. 2004;251:454‐457. doi:10.1007/s00415-004-0355-x
Gahr M, Orth M, Abler B. Neuroleptic malignant syndrome with aripiprazole in Huntington's disease. Mov Disord Off J Mov Disord Soc. 2010;25:2475‐2476. doi:10.1002/mds.23332
Moreno JLL‐S, Palau Fayos JM, Díaz de Santiago A, García de Yébenes J. Neuroleptic malignant syndrome induced by olanzapine in a patient with Huntington's disease. J Huntingt Dis. 2012;1:31‐32. doi:10.3233/JHD-2012-120008
Nozaki I, Furukawa Y, Kato‐Motozaki Y, et al. Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and tiapride in a Japanese patient with Huntington's disease at the terminal stage of recurrent breast cancer. Intern Med Tokyo Jpn. 2014;53:1201‐1204. doi:10.2169/internalmedicine.53.1717
Sathe S, Ware J, Levey J, et al. Enroll‐HD: an integrated clinical research platform and worldwide observational study for Huntington's disease. Front Neurol. 2021;12:667420. doi:10.3389/fneur.2021.667420
Trollor JN, Chen X, Chitty K, Sachdev PS. Comparison of neuroleptic malignant syndrome induced by first‐ and second‐generation antipsychotics. Br J Psychiatry J Ment Sci. 2012;201:52‐56. doi:10.1192/bjp.bp.111.105189
Belvederi Murri M, Guaglianone A, Bugliani M, et al. Second‐generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs RD. 2015;15:45‐62. doi:10.1007/s40268-014-0078-0
Dazzan P, Morgan KD, Orr K, et al. Different effects of typical and atypical antipsychotics on Grey matter in first episode psychosis: the ÆSOP study. Neuropsychopharmacology. 2005;30:765‐774. doi:10.1038/sj.npp.1300603
Sarkar S, Gupta N. Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: nuances and pragmatics of the association. BJPsych Bull. 2017;41:211‐216. doi:10.1192/pb.bp.116.053736
Khaldi S, Kornreich C, Choubani Z, Gourevitch R. Neuroleptic malignant syndrome and atypical antipsychotics: a brief review. L'Encephale. 2008;34:618‐624. doi:10.1016/j.encep.2007.11.007
Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease. Neurology. 2006;66:366‐372. doi:10.1212/01.wnl.0000198586.85250.13
Chen JJ, Ondo WG, Dashtipour K, Swope DM. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther. 2012;34:1487‐1504. doi:10.1016/j.clinthera.2012.06.010
Kyotani Y, Zhao J, Nakahira K, Yoshizumi M. The role of antipsychotics and other drugs on the development and progression of neuroleptic malignant syndrome. Sci Rep. 2023;13:18459. doi:10.1038/s41598-023-45783-z